Evidence map›Paper›PMID 29760808›Full record

ArticleJournal of Cancer2018

PIASy antagonizes Ras-driven NSCLC survival by promoting GATA2 SUMOylation.

Bin Chen, Jie Luo, Yirui Zhou, Xu Xin, Rong Cai, Chunhua Ling

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Cancer-Associated Dysregulation of Sumo Regulators: Proteases and Ligases.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Bin ChenDepartment of Oncology, Shanghai Pulmonary Hospital, Shanghai Tongji University, Shanghai 200433, China.
Jie LuoDepartment of Oncology, Shanghai Pulmonary Hospital, Shanghai Tongji University, Shanghai 200433, China.
Yirui ZhouDepartment of Oncology, Shanghai Pulmonary Hospital, Shanghai Tongji University, Shanghai 200433, China.
Xu XinDepartment of Oncology, Shanghai Pulmonary Hospital, Shanghai Tongji University, Shanghai 200433, China.
Rong CaiDepartment of Biochemistry & Molecular Cell Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Chunhua LingDepartment of Respiratory Diseases, the First Affiliated Hospital of Soochow University, Suzhou 215000, China.
Tongji University · CNFirst Affiliated Hospital of Soochow University · CNShanghai Jiao Tong University · CNSoochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

GATA2 regulated transcriptional network has been validated requisite for RAS oncogene-driven non-small cell lung cancer (NSCLC). GATA2 has been reported as a SUMOylated protein. In endothelial cells, its transcriptional activity is attenuated by SUMO-2 conjugation, which is specifically catalyzed by its E3 ligase PIASy. In this study, we found a decreased expression of PIASy in RAS mutant NSCLC cell lines and specimens with RAS mutations. Forced expression of PIASy in NSCLC cells inhibits their viability

Indexed as

GATA2NSCLCPIASyRasSUMOylaition

Identifiers

PMID29760808
PMCPMC5950599
OpenAlexW2799692677

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.